Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/197869
Inhaled corticosteroids for the treatment of COVID-19
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms
Matèries
Matèries (anglès)
Citació
Citació
BAFADHEL, Mona, FANER, Rosa, TAILLÉ, Camille, RUSSELL, Richard e. k., WELTE, Tobias, BARNES, Peter j., AGUSTÍ GARCÍA-NAVARRO, Àlvar. Inhaled corticosteroids for the treatment of COVID-19. _European Respiratory Review_. 2022. Vol. 31, núm. 220099. [consulta: 7 de febrer de 2026]. ISSN: 0905-9180. [Disponible a: https://hdl.handle.net/2445/197869]